Entry Point Capital, LLC Pacira Bio Sciences, Inc. Transaction History
Entry Point Capital, LLC
- $171 Million
- Q3 2024
A detailed history of Entry Point Capital, LLC transactions in Pacira Bio Sciences, Inc. stock. As of the latest transaction made, Entry Point Capital, LLC holds 15,959 shares of PCRX stock, worth $264,919. This represents 0.14% of its overall portfolio holdings.
Number of Shares
15,959Holding current value
$264,919% of portfolio
0.14%Shares
3 transactions
Others Institutions Holding PCRX
# of Institutions
266Shares Held
50.6MCall Options Held
429KPut Options Held
391K-
Black Rock Inc. New York, NY8.01MShares$133 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.3MShares$88 Million0.0% of portfolio
-
Pacer Advisors, Inc. Malvern, PA4.96MShares$82.4 Million0.18% of portfolio
-
State Street Corp Boston, MA2.01MShares$33.4 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny1.98MShares$32.9 Million0.05% of portfolio
About Pacira BioSciences, Inc.
- Ticker PCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 45,824,200
- Market Cap $761M
- Description
- Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...